Motif Neurotech, a neurotechnology company based in Houston, TX, has raised $18.75 million in Series A funding. The funding round was led by Arboretum Ventures and included participation from new investors KdT Ventures, Satori Neuro, Dolby Family Ventures, re.Mind Capital, and existing investors Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures, and Capital Factory. The company plans to use the funding to further develop its lead product, the DOT microstimulator, which is a miniature brain pacemaker designed to treat mental health disorders by precisely stimulating the brain to restore healthy circuit activity.
Motif Neurotech is focused on developing wireless minimally-invasive neuromodulation therapeutics for mental health. The company’s lead product is a miniature implant being developed for the treatment of treatment-resistant depression (TRD). The implant is enabled by wireless magnetoelectric empower transfer technology developed at Rice University. The DOT microstimulator is a wireless, battery-free device that can be implanted in a 20-minute outpatient procedure and allows for at-home therapy.
According to Motif Neurotech CEO and Founder Jacob Robinson, approximately 30% of patients with depression do not respond to two or more medications, indicating a significant need for additional treatment options. The company plans to use the Series A funding to bring the DOT microstimulator into a clinical study for patients with TRD.
